Targeting SLC2A1 activity seems to be a promising strategy for the treatment of cancer with prominent hypoxic response and Warburg effect; however, utility of SLC2A1 inhibitors in MPNST is yet to be established. The gene discussed is SLC2A1; the disease is malignant peripheral nerve sheath tumor.